

(12) UK Patent Application (19) GB (11) 2 133 401 A

(21) Application No 8311508
 (22) Date of filing 27 Apr 1983
 (30) Priority data
 (31) 8207203
 (32) 27 Apr 1982
 (33) France (FR)
 (43) Application published
 25 Jul 1984
 (51) INT CL³
 C07D 487/10 A61K 31/47
 31/65 // C07C 101/12
 C07D 217/24 223/16 (C07D
 487/10 217/00 223/00
 233/00)

(52) Domestic classification
 C2C 1414 1535 1732 211
 213 215 220 226 227 22Y
 246 247 250 251 252 25Y
 2BX 29X 29Y 302 305 30Y
 311 313 31Y 323 32Y 337
 338 351 352 355 35Y 360
 362 364 366 368 36Y 386
 388 396 401 40Y 456 45Y
 491 553 613 615 620 623
 624 625 628 635 645 650
 658 65X 668 672 675 698
 699 760 761 764 775 802
 80Y AA LS GS TL TY UH
 U1S 1316 C2C

(56) Documents cited
 None

(58) Field of search
 C2C


(71) Applicant
 ADIR
 (France),
 22 rue Garnier, 92201
 Neuilly-sur-Seine, France

(72) Inventors
 Charles Malen,
 Jean-Louis Peglion,
 Jacques Duault,
 Michelle Boulanger

(74) Agent and/or Address for
 Service
 Abel & Imray,
 Northumberland House,
 303—306 High Holborn,
 London WC1V 7LH

(54) Benzoazacycloalkyl-spiro-
 imidazolidines

(57) The present invention provides a
 compound of the general formula:



In which

—R₁ represents a halogen or a
 hydrogen atom, or a hydroxy or
 methoxy group,

—R₂ represents a hydrogen atom, a
 lower alkyl radical, a phenyl-lower alkyl
 radical, a lower alkanoyl radical or a
 p-toluenesulphonyl group, and

—n represents 1 or 2,
 in the racemic form or as an optical
 isomer, or salts thereof and a process
 for their preparation. These compounds
 are useful in the treatment of diabetes.

I


GB 2 133 401 A

SPECIFICATION

Benzoazacycloalkyl-spiro-Imidazolidines, their preparation and the pharmaceutical compositions containing them

The present invention relates to benzoazacycloalkyl-spiro-Imidazolidines, a process for preparing them, and pharmaceutical compositions containing them.

The invention provides benzoazacycloalkyl-spiro-imidazolidines of the general formula:



in which:

R₁ represents a hydrogen or a halogen atom or a hydroxy or a methoxy group.

R₂ represents a hydrogen atom, a lower alkyl radical, a phenyl-lower alkyl radical, a lower alkanoyl radical or a *p*-toluenesulphonyl group, and

n represents 1 or 2;

and salts thereof.

Salts of compounds of the general formula I may be obtained with mineral or organic bases, or may be acid addition salts (except when R₂ represents an alkanoyl radical or *p*-toluenesulphonyl group) obtained with, for example, mineral acids. Preferably, the salts are physiologically tolerable.


Because the compounds I have an asymmetric carbon atom (spiro bond), they may exist in racemic form, or as optical isomers, and these individual isomers, as well as the racemates, form part of the invention. Thus, it should be understood that the structural formulae and written nomenclature of the compounds described and claimed herein include, unless otherwise indicated, the individual isomers and the mixtures of the isomers.

The term "lower" used in connection with alkyl radicals or moieties or with alkanoyl radicals denotes such radicals and moieties that have from 1 to 4 carbon atoms. Thus, for example, R₂ may represent a formyl, acetyl or propionyl group or a benzyl group.

Preferred compounds are those in which R₂ represents a hydrogen atom.


The radical represented by R₁ may be in any free position on the benzene ring, for example the 6, 7 or 8 position. Compounds with a 7-methoxy or a 6- or 8-halo substituent should especially be mentioned.

The present invention also provides a process for preparing a compound of the general formula I or 30 a salt thereof, which comprises condensing a ketone of the general formula:



II

in which R₂' has the meaning given for R₂ above except that it may not represent a hydrogen atom, and R₁ and n have the meanings given for formula I, with an alkali metal cyanide in the presence of ammonia or an ammonium salt, to provide a spiro-hydantoin of the general formula:



I'

35

35

In which n, R₁ and R₂' have the meanings given for formula II, and, if desired, converting a compound of the general formula I' into a compound of the general formula I in which R₂ represents a hydrogen atom and/or into another compound of the general formula I or into a salt thereof. For example, a compound of the formula I' may be debenzylated to give a compound with the formula I in which R₂ represents H, and this latter may be submitted to an acylation by means of a lower alkanolic acid halide or *p*-toluenesulphonyl halide, to obtain the corresponding compound with the formula I in which R₂ represents a lower alkanoyl radical or *p*-toluenesulphonyl group.

The condensation reaction of the ketone (III) with the alkali metal cyanide may be carried out for


example under the usual conditions of the Strecker reaction, in the presence of ammonia or of an ammonium salt in a polar solvent, such, for example, as alcohol, at boiling point and if necessary under pressure.

Debenzylation of the spiro-hydantoin (I') may be carried out for example by hydrogen in the

5 presence of a catalyst such, for example, as Pd/C in a polar solvent.

Acylation may be carried out for example in the presence of an acid acceptor, which can serve as a solvent, for example pyridine.

Starting materials of the general formula II in which n represents 1 (isoquinolones) are described in the literature (The Chemistry of Heterocyclic Compounds, vol. 38.1, p. 215-216, Interscience, Wiley 10 Editor), or they may be prepared starting from benzoic esters according to the following reaction scheme:



In these various formulae, R₁ and R₂' have the same meanings as in formula II and X represents a halogen atom, preferably Br.

15 The benzoic ester (V) may for example be condensed with an N-substituted ethyl glycinate in the presence of an acid acceptor such, for example, as triethylamine at reflux, then the diester (IV) cyclised to the ketone (III) by means of an alkaline alcoholate such, for example, as sodium ethylate in ethanol at reflux. The ketone (III) may then be decarboxylated by a strong acid in an aqueous medium to give the ketone derivative (II; n = 1).

20 Starting materials of the general formula II in which n represents 2 (benzazepinones) may be prepared starting from the corresponding alcohols of the general formula:



In which R₁ has the same meaning as in formula I; the synthesis of such alcohols is described by M. LENNON et al., (J. Chem. Soc. 1975, 622). These compounds are acylated, alkylated or aralkylated on the nitrogen atom, and then the hydroxy group is oxidised to provide the corresponding ketone (II; n = 2).

The following Examples illustrate the preparation of the compounds according to the invention.

EXAMPLE 1

6-chloro-2-benzyl-1,2,3,4-tetrahydro-isoquinoline-4-spiro-4'-imidazolidine-2',5'-dione

30 a) Ethyl N-(4-chloro-2-ethoxycarbonyl-benzyl)-N-benzyl-glycinate.

55.5 g (0.2 M) of ethyl 5-chloro-2-bromoethyl-benzoate is dissolved in 270 ml of ethyl oxide taken to reflux and 34.78 g (0.18 M) of ethyl N-benzylglycinate as well as 18.62 g (0.184 M) of triethylamine are added by successive fractions over 12 hours, and left at reflux for a total of 35 hours. After cooling, 150 ml of water and 80 ml of 2.5 N NaOH are added. The organic phase is decanted and submitted to an acid/base treatment. 43.8 g of product is obtained in the form of an oil (Yield 61%).

30

35

I.R.: C = O 1730 cm⁻¹

NMR: 8H (ar.) 7.5 ppm 4H (q) 4.3 ppm
 2H (s) 4.2 ppm 2H (s) 3.8 ppm
 2H (s) 3.3 ppm 6H (t) 1.3 ppm

5 b) 6-chloro-3-ethoxycarbonyl-2-benzyl-1,2,3,4-tetrahydro-4-isoquinolone.

26.9 g (0.069 M) of the crude ester obtained at a) above is dissolved in 350 ml of benzene and over 90 minutes this solution is poured into a solution of 2.1 g of sodium ethylate in 50 ml of ethanol. The reaction mixture is taken to reflux for one hour, then cooled and treated with dilute hydrochloric acid until neutral. The benzene phase is decanted, washed with water, dried and the solvent evaporated. 22.9 g of crystallised product is obtained.

5

10 M.P. = 71—76°C (Minikofler).

10

After recrystallisation from 40 ml of ethanol, 19 g of product is obtained (Yield 80%), M.P. = 75—77°C (M.K.)

I.R.: C = O (ester) 1640 cm^{-1} C = C—OH 1610 cm^{-1}

NMR: Confirmation of the enol form; 1H exchangeable at 11.6 ppm.

15 c) 6-chloro-2-benzyl-1,2,3,4-tetrahydro-4-isoquinolone.

15

26.1 g (0.076 M) of the compound obtained at b) is added to 130 ml of ethanol and 400 ml of 10 N (aqueous) HCl and taken to reflux for 12 hours. After elimination of the greater part of the ethanol, the hydrochloride of the compound sought precipitates. After separating, washing and drying, 19 g of crude product is obtained.

20 The base is obtained by partition between dichloromethane and 5 N sodium hydroxide.

20

16.1 g M.P. = 82—83°C (M.K.)

Recrystallising from 35 ml of isopropyl oxide provides,
 14.2 g (Yield 69%) M.P. = 83—85°C (M.K.)

I.R.: C = O 1690 cm^{-1}

25 26 NMR: 8H (ar.) 7—8 ppm 4H (s) 3.8 ppm
 2H (s) 3.4 ppm

25

d) 6-chloro-2-benzyl-1,2,3,4-tetrahydro-isoquinoline-4-spiro-4'-imidazolidine-2',5'-dione.

13.8 g (0.051 M) of isoquinoline obtained at c), 4.97 g (0.0765 M) of potassium cyanide and 24.48 g (0.255 M) of ammonium carbonate in 170 ml of ethanol are put into an autoclave and taken to 30 115° for 22 hours. After cooling, and evaporation of the solvent, the residue is taken up by 50 ml of water. The solution is acidified to pH 1, and by separating, washing with water and then with methanol, 13.2 g of product is obtained.

30

(Yield 76%) M.P. = 260°C (M.K.)

I.R.: C = O 1720 cm^{-1} to 1770 cm^{-1}

35 36 NMR: 8H (ar.) 7—7.5 ppm 4H (m) 3.5—3.8 ppm
 2H (s) 2.9 ppm

35

EXAMPLE 2

6-chloro-1,2,3,4-tetrahydro-isoquinoline-4-spiro-4'-imidazolidine-2',5'-dione

3.1 g (0.009 M) of the spiro-hydantoin obtained at Example 1 is hydrogenated in 60 ml of acetic acid, at 60°C under ordinary pressure, and in the presence of 500 mg of Pd at 10% on charcoal.

40

After absorption of the theoretical volume of hydrogen, the solvent is filtered and evaporated. The residue is crystallised from a water-ethanol mixture. 1.4 g of product is obtained.

(Yield 63%) M.P. = 234—238°C (M.K.)

EXAMPLE 3

45 6-chloro-2-acetyl-1,2,3,4-tetrahydro-isoquinoline-4-spiro-4'-imidazolidine-2',5'-dione

2.51 g (0.01 M) of the compound obtained at Example 2 is acetylated by acetyl chloride in the presence of pyridine at ambient temperature. The crude acetylated product is isolated and crystallised from methanol. 1.4 g is obtained.

45

M.P. = 252—254°C (M.K.)

I.R. (DMSO): NH 3500—2500 cm⁻¹

C = O 1700 and 1765 cm⁻¹ (imidazolinone)

C = O 1640 cm⁻¹ (acetyl).

5 EXAMPLE 4

3-acetyl-2,3,4,5-tetrahydro-benzo[d]1-H-azepine-5-spiro-4'-imidazolidine-2',5'-dione

a) 1-hydroxy-3-acetyl-2,3,4,5-tetrahydro-benzo[d]1-H-azepine.

7 g (0.043 M) of 1-hydroxy-benzo[d]perhydro-azepine, prepared according to LENNON and al (J. Chem. Soc. 1975, 622) is acetylated by acetyl chloride at ambient temperature. The acetylated derivative is isolated and crystallised from acetonitrile.

5

10

5.5 g is obtained (Yield 63%) M.P. = 113—116°C (M.K.)

I.R OH 3200 cm⁻¹ CO 1620 cm⁻¹

b) 3-acetyl-2,3,4,5-tetrahydro-benzo[d]1-H-azepin-1-one

4.5 g (0.002 M) of acetyl-benzazepinol obtained at a) is oxidised by 15.4 g of complex CrO₃ · 2

15 pyridine in 200 ml of acetone. After the usual treatment, 3 g of product is isolated after distillation under vacuum.

15

B.P.: 0.001 mm (pressure) = 180°C

I.R.: CO (amide 1650 cm⁻¹ CO (ketone 1690 cm⁻¹)

c) 3-acetyl-2,3,4,5-tetrahydro-benzo[d]1-H-azepine-5-spiro-4'-imidazolidine-2',5'-dione

20 By operating as in Example 1 d) but starting with 3.5 g (0.017 M) of perhydroazepinone obtained at b) above, (instead of isoquinoline) 1.67 g (0.026 M) of KCN and 8.16 g (0.085 M) of (NH₄)₂CO₃, 2.4 g of the product sought is obtained after crystallising from methanol.

20

M.P. = 268—276°C (M.K.)

I.R.: CO (hydantoin) 1770 cm⁻¹ and 1720 cm⁻¹

25 CO (acetyl) 1660 cm⁻¹

25

EXAMPLE 5

Optical isomers of 6-chloro-1,2,3,4-tetrahydro-isoquinoline-4-spiro-4'-imidazolidine-2',5'-dione

a) Camphosulphonate of the (d) isomer

30 100 g (0.336 M) of the racemic compound obtained according to Example 2, 78 g (0.336 M) of (I)-10-camphosulphonic acid, 1300 cm³ of water and 400 cm³ of ethanol are taken to reflux until complete dissolution. The solution obtained is concentrated to dryness which yields 162 g of the product sought, the product is crystallised from 3200 cm³ methanol, and 70.7 g precipitates after one night in the refrigerator at 3°C. A second crystallisation from 2950 cm³ methanol, 24 hours in the freezer at —18°C yields 54.6 g of (d)-6-chloro-1,2,3,4-tetrahydro-isoquinoline-4-spiro-4'-imidazolidine-2',5'-dione.

30

35 (I)-10-camphosulphonate.

35

M.P. = 257°C (decomposition)

$\alpha_{589}^{21^\circ} = +24.6$ $\alpha_{436}^{21^\circ} = +44$ (0.5% in CH₃OH)

b) (d)-isomer

40 13.8 g (0.0285 M) of the camphosulphonate obtained hereabove is suspended in 145 cm³ of an aqueous solution of 2% triethylamine. The suspension is heated on a water bath until a neutral pH solution is obtained, which is left overnight in the refrigerator at 3°C; 6.8 g of (d)-6-chloro-1,2,3,4-tetrahydro-isoquinoline-4-spiro-4'-imidazolidine-2',5'-dione precipitates.

40

M.P. = 252°C (decomposition and sublimation)

$\alpha_{589}^{22^\circ} = +44.4$ $\alpha_{436}^{22^\circ} = +86.4$ (0.4% in CH₃OH)

c) Hydrochloride of the (*d*)-isomer

6.4 g (0.0255 M) of the free base obtained above is suspended in 15.4 cm³ of 1.65 N hydrochloric acid. After 20 minutes contact, then 3 hours in the refrigerator (3°C), 6.7 g of the hydrochloride is obtained.

5 M.P. = 245°C

5

$$\alpha_{589}^{22^\circ} = +78.3 \quad \alpha_{438}^{22^\circ} = +177.7 \text{ (0.5% in CH}_3\text{OH)}$$

d) (*l*)-isomer

The operation is exactly the same as for the separation of the (*d*)-isomer above, but starting from 10 (*d*)-10-camphorsulphonic acid (instead of the (*l*)) so as to obtain the (*l*)-6-chloro-1,2,3,4-tetrahydro-isoquinoline-4-spiro-4'-imidazolidine-2',5'-dione, (*d*)-10-camphorsulphonate. The physical data are of course the same as those of the (*d*)-isomer, the rotatory power being inverted.






The optical purity of the isomers was verified and was found higher than 98%.

15 The compounds obtained in the preceding Examples as well as other compounds with the formula I given by way of non limitative examples and prepared in a similar manner are summarised in the following table. The formula of each of the compounds has been verified by centesimal analysis and their structure by I.R. and NMR.

10

15

TABLE

Compound No.	n	R ₁	R ₂	m.p. (°C)	Preparation
1	1	7-CH ₃ O		243-6	as ex. 1
2	1	7-CH ₃ O	H	245-9	as ex. 2
3	1	7-CH ₃ O	CH ₃ - 	208-10	as ex. 1
4	2	H	CH ₃ - 	262-3	as ex. 1
5	1	7-CH ₃ O	CH ₃ CO	235-5 (HCl)	as ex. 3
6	1	6-Cl	H	234-8	example 2
7	1	6-Cl		260 (dec.)	example 1
8	1	6-Cl	CH ₃ CO-	252-4	example 3
9	2	H	CH ₃ CO-	268-76	example 4
10	1	6-Cl	CH ₃ CH ₂ CO-	225-7	as ex. 3
11	1	H	H	260 HCl (dec.)	as ex. 2
12	1	H		255-60	as ex. 1
13	1	6-F		275-80 (dec.)	as ex. 1
14	1	6-F	H	265 (dec.)	as ex. 2
15		(d) Isomer of compound No. 6		252 (dec.)	example 5b
16		(I) Isomer of compound No. 6		252 (dec.)	example 5d
17	1	8-Cl		195-207 (HCl)	as ex. 1
18	1	8-Cl	H	270 (dec.) (HCl)	as ex. 2

Pharmacological study of the compounds according to the invention

1. The compounds according to the invention have been tested for their inhibiting action on aldose-reductase extracted from the crystalline lens of rats according to the technique described by S. HAYMAN and J. H. KINOSHITA, *J. Biol. Chem.* 240 (1965) 877, modified by S. D. WARNA and J. H. KINOSHITA, *Biochemical Pharmacology* 5 (1976), 2505—2613. 5

The products according to the invention dissolved in a pH 6.2 buffer are incubated at 25°C in a stoppered recipient containing the aldose-reductase extracted from the crystalline lens of CD River rats. After 10 minutes of contact the substrate is added and the activity of the enzyme is judged by the disappearance from the medium of the co-factor nicotinamide adenine dinucleotide phosphoric acid (NADPH) reduced according to the reaction: 10



The enzyme activity is calculated by determining the quantity of NADPH which has disappeared. The results are expressed as a percentage of the enzyme activity of the preparation in the absence of any inhibitor. Under these conditions the minimum dose which inhibits the aldose-reductase by 100% and the minimum which inhibits the enzyme activity by 50% can be determined. 15

The compounds according to the invention were tested at concentrations varying between 10^{-8} and 10^{-6} M. Generally, inhibition of the enzyme preparation by 50% was obtained with a concentration of 10^{-7} M. 15

2. The toxicity of the compounds according to the invention is very weak and the LD₅₀ determined on Swiss mice is greater than 1 g/kg by the intraperitoneal route. 20

3. The activity *in vivo* of the compounds has been studied on rats rendered diabetic by intravenous injection of streptozotocine at 65 mg/kg. 20

The products tested were administered in suspension in a gummy solution (20%) by the oral route morning and evening. The animals were induced to eat their food between hours 8 and 16. 25

After 7 days treatment, the animals were killed by decapitation. The blood was gathered for measurement of the glycaemia by the glucose-oxidase method. The crystalline lenses were removed immediately after death, rapidly weighed and plunged into liquid nitrogen. The frozen crystalline lenses were pulverized in an aqueous solution of sedoheptulose utilised as an internal standard for gaseous phase chromatography determination. The proteins were precipitated. After centrifuging, the supernatant was recovered and lyophilized. The dried extract was silylated by TMCS/HDMDS and taken up in heptane for chromatography by means of a "Hewlett Packard 5710" chromatograph under the following conditions: Detection FID, column 2.5 m, 3 mm, 9% E.G.S. chrome G AWDMCS 80—100 mesh (0.15—0.18 mm) temperature 170°C, gas vector: nitrogen (30 ml/min). 30

The results showed that the compounds of the invention, at a daily dose of $2 \times (1$ to $5)$ mg/kg p.o., reduced by 70 to 100% the content of sorbitol in the crystalline lens of rats rendered diabetic (glycaemia 4.0 ± 0.4 g/l). 35

Therefore the compounds according to the invention possess useful pharmacological properties. In particular, the exhibit inhibiting properties for the aldose-reductase enzyme, the principal enzyme which controls the regulation of the metabolism of the aldoses and, in particular, the aldohexoses such as glucose and galactose, by transforming them into the corresponding polyol (sorbitol or galactitol for example) in the human organism. 40

Excess functioning of such an enzyme in the presence of an excess of substrate can cause an abnormally elevated production of galactitol or sorbitol in galactosemic subjects. Abnormal concentrations of polyols cause accumulations of these substances in the crystalline lens, in the peripheral nerves and in the kidneys of diabetic subjects. In fact, the intervention of aldose-reductase present in the tissues is hardly noticeable in a subject with normal glycaemia. Its role becomes much more important in diabetic subjects who have a much higher glycaemia. 45

In this way there is explained a modification of the capillary functions, of nerve conduction disorders and of the appearance of a diabetic cataract with loss of transparency of the crystalline lens. 50

Compounds of the invention may be helpful in reducing or totally avoiding these serious complications. 50

Moreover the compounds according to this invention decrease the prolactin secretion by the rat's hypophysis *in vitro* at a concentration of 10^{-6} M and above and *in vivo* at doses from 2 to 20 mg/kg. The basal secretion of the growth hormone is not modified in these conditions, but the hypersecretion provoked by a sympathetic stress is inhibited, which property can be of particular interest in the treatment of diabetics. 55

Consequently, compounds of the general formula I and their physiologically tolerable salts may be used for the treatment of diabetes, in particular, for combating the increase in the capillary permeability at the origin of retinopathy and trophic disorders, the prevention or the treatment of diabetic neuropathy. 60

In its peripheral or visceral manifestations and the prevention and the treatment of cataract and of diabetic nephropathy.

The present invention accordingly provides a pharmaceutical preparation which comprises a

compound of the general formula I or a physiologically tolerable salt thereof, in admixture or conjunction with a pharmaceutically suitable carrier. The preparation may, for example, be in dosage unit form.

Preferably, the compounds of the invention are administered by the oral or parenteral route. The pharmaceutical forms which are most particularly suitable for such administrations include solutions and suspensions which are injectable, prepared in ampoules or in auto-injectable syringes; plain and 5 coated tablets; sugar coated tablets; capsules; pills; drinkable syrups and emulsions; ointments; drops; collyria; and ophthalmic gels and saccules (for the eyes).

The unit posology may vary according to the route of administration, the age of the patient and the 10 severity of the therapeutic indication. It may range for example from 25 to 250 mg per unit dose. The daily posology may range for example from 50 to 500 mg in an adult.

EXAMPLE OF A CAPSULE (EXAMPLE A)

6-chloro-2-benzyl-1,2,3,4-tetrahydro-isoquinoline-4-spiro-4'-imidazolidine-2',5'-dione 50 mg


lactose 40 mg

15 talc 10 mg 15

for one capsule.

CLAIMS

1. A compound of the general formula:



20 in which 20

— R₁ represents a halogen or a hydrogen atom, or a hydroxy or methoxy group,
— R₂ represents a hydrogen atom, a lower alkyl radical, a phenyl-lower alkyl radical, a lower alkanoyl radical or a p-toluenesulphonyl group, and
— n represents 1 or 2,

25 In the racemic form or as an optical isomer. 25

2. A compound as claimed in claim 1, in which R₂ represents a hydrogen atom.

3. 6-Chloro-2-benzyl-1,2,3,4-tetrahydro-isoquinoline-4-spiro-4'-imidazolidine-2',5'-dione.

4. 6-Chloro-1,2,3,4-tetrahydro-isoquinoline-4-spiro-4'-imidazolidine-2',5'-dione or its (I) or (d) isomer.

30 5. 6-Fluoro-1,2,3,4-tetrahydro-isoquinoline-4-spiro-4'-imidazolidine-2',5'-dione. 30

6. 3-Acetyl-benzo-[d]-azepine-1-spiro-4'-imidazolidine-2',5'-dione.

7. A compound as claimed in claim 1, which is any one of those shown in the Table hereto.


8. A salt of a compound claimed in any one of claims 1 to 7.

9. A salt of a compound claimed in any one of claims 1 to 7 with a mineral or organic base.

35 10. An acid addition salt of a compound claimed in any one of claims 1 to 5 and 7, with the exception of a compound in which R₂ represents an alkanoyl radical or p-toluenesulphonyl group. 35


11. A salt as claimed in any one of claims 8 to 10, which is physiologically tolerable.

12. A process for the preparation of a compound as claimed in claim 1 or a salt thereof, which comprises condensing a compound of the general formula



40 II 40

in which R₂' has the meaning given for R₂ in claim 1, except that it may not represent a hydrogen atom, and R₁ and n have the meanings given in claim 1, or a salt thereof, with an alkali metal cyanide in the presence of ammonia or an ammonium salt to provide a compound of the general formula



I'

in which n, R₁ and R₂' have the meanings given above, or a salt thereof, and, if desired, carrying out one or more of the following steps in any appropriate order:

5 13. A process as claimed in claim 12, in which a compound of the general formula I' is converted into a compound of the general formula I given in claim 5
 1 in which R₂' represents a hydrogen atom; converting a compound of the general formula I into another compound of the general formula I; converting a compound of the general formula I' or I into a salt thereof.

10 14. A process as claimed in claim 12 or claim 13, in which a compound of the general formula I in which R₂' represents a phenyl-lower alkyl radical is converted into a compound of the general formula I in which R₂' represents a hydrogen atom.

15 15. A process as claimed in claim 12, carried out substantially as described in any one of the Examples herein.

16. A compound as claimed in claim 1, whenever prepared by a process as claimed in any one of claims 12 to 15.

20 17. A salt of a compound claimed in claim 1, whenever prepared by a process as claimed in any one of claims 12 to 15.

25 18. A physiologically tolerable salt of a compound claimed in claim 1, whenever prepared by a process as claimed in any one of claims 12 to 15.

19. A pharmaceutical preparation which comprises a compound as claimed in any one of claims 1 to 7, 11, 16 and 18, in admixture or conjunction with a pharmaceutically suitable carrier.

20 20. A pharmaceutical preparation as claimed in claim 19, which is in dosage unit form.

21. A pharmaceutical preparation as claimed in claim 20, which contains from 25 to 250 mg of active ingredient per dosage unit.

22. A pharmaceutical preparation as claimed in claim 19, substantially as described in Example A herein.

ENGLISH ABSTRACT FOR SU1238732

1 / 1 WPAT - The Thomson Corp.
Derwent Accession : 1983-56711K [24]
CPI Accession : C1983-055068
Title : Alpha-2 antagonist compsn. contg. 3-benzazepine cpd. esp. for reducing intra-ocular pressure and blood pressure
Derwent Class : B02
Patent Assignee : (SMIK) SMITHKLINE BECKMAN CORP
Inventor : DEMARINIS RM; HIEBLE JP; MATTHEWS WD
Nbr of Patents : 19
Nbr of Countries : 27
Patent Number : EP--80779 A 19830608 DW1983-24 Eng 29p *
AP: 1982EP-0201507 19821129
JP58092616 A 19830602 DW1983-28 Jpn
AP: 1982JP-0201817 19821116
AU8290172 A 19820602 DW1983-29 Eng
AP: 1982AU-0090172 19821104
NO8203990 A 19830620 DW1983-31 Nor
AP: 1982NO-0003990 19821126
FI8203715 A 19830729 DW1983-36 Fin
AP: 1982FI-0003715 19821101
DK8204931 A 19830801 DW1983-37 Dan
AP: 1982DK-0004931 19821105
HUT027615 T 19831028 DW1983-49 Hun
PT--75838 A 19831207 DW1984-02 Por
AP: 1982PT-0075838 19821112
ZA8207887 A 19831018 DW1984-05 Eng
AP: 1982ZA-0007887 19821028
DD-205896 A 19840111 DW1984-19 Ger
AP: 1982DD-0245313 19821129
US4465677 A 19840814 DW1984-35 Eng
AP: 1982US-0398015 19820714
CS8208075 A 19840717 DW1984-40 Cze
ES8405769 A 19841001 DW1984-49 Spa
AP: 1982ES-0517697 19821126
RO--85262 A 19841030 DW1985-18 Rum
AP: 1982RO-0109135 19821125
EP--80779 B 19860716 DW1986-29 Eng
AP: 1982EP-0201507 19821129

DE3272044 G 19860821 DW1986-35 Ger

CA1214165 A 19861118 DW1986-51 Eng
AP: 1982CA-0414027 19821022

SU1238732 A 19860615 DW1987-05 Rus
AP: 1982SU-3513948 19821125

IL--67092 A 19870916 DW1987-47 Eng.
AP: 1982IL-0067092 19821027

Priority Number :
1982EP-0305361 19821008; 1981US-0325249 19811127; 1982US-0398015 19820714

Intl Patent Class :
C07D-223/16; A61K-031/33; A61K-031/55; A61P-025/02; A61P-027/02;
A61P-027/06; A61P-009/12; C07D-233/00; C07D-233/16; C07D-223/00;
A61K-000/00; A61P-025/00; A61P-027/00; A61P-009/00; C07C-000/00;
C07D-000/00

Advanced IPC (V8) :
C07D-223/16 [2006-01 A F I R - -]; A61K-031/33 [2006-01 A - I R - -];
A61K-031/55 [2006-01 A L I R - -]; A61K-031/55 [2006-01 A - I R - -];
A61P-025/02 [2006-01 A L I R - -]; A61P-027/02 [2006-01 A L I R - -];
A61P-027/06 [2006-01 A L I R - -]; A61P-009/12 [2006-01 A L I R - -];
C07D-223/16 [2006-01 A - I R - -]; C07D-233/00 [2006-01 A - I R - -];
C07D-233/16 [2006-01 A - I R - -]

Core IPC (V8) :
C07D-223/00 [2006 C F I R - -]; A61K-000/00 [2006 S - I R - -];
A61K-031/33 [2006 C - I R - -]; A61K-031/55 [2006 C L I R - -];
A61K-031/55 [2006 C - I R - -]; A61P-025/00 [2006 C L I R - -];
A61P-027/00 [2006 C L I R - -]; A61P-009/00 [2006 C L I R - -];
C07C-000/00 [2006 S - I R - -]; C07D-000/00 [2006 S - I R - -];
C07D-223/00 [2006 C - I R - -]; C07D-233/00 [2006 C - I R - -]

US Patent Class :
514213000 540594000

Designated States :
EP--80779

Regional States: AT BE CH DE FR GB IT LI LU NL SE
EP--80779

Regional States: AT BE CH DE FR GB IT LI LU NL SE

Abstract :
EP--80779 A
An alpha-2 antagonist compsn. comprises a carrier and a 3-benzazepine cpd. of formula (I) or its pharmaceutically acceptable acid addn. salt. (R is 1-3C alkyl or allyl. X is halo). Most pref. (I) is 6-chloro-2,3,4,5-tetrahydro-3-methyl-1H-benzazepine (Ia) used as its hydrochloride salt. Esp. (I) are used to reduce intraocular pressure (treatment of glaucoma); as cardiovascular agents (treatment of congestive heart failure, angina pectoris and thrombosis) and as antihypertensives. They have no direct effect on pupil size and no effect on heart rate or blood pressure in normotensive subjects.

Manual Codes :
CPI: B06-D04 B12-E01 B12-F01 B12-F02 B12-F05 B12-H02 B12-L04

Update Basic :
1983-24

Update Equiv. :
1983-28; 1983-29; 1983-31; 1983-36; 1983-37; 1983-49; 1984-02; 1984-05;
1984-19; 1984-35; 1984-40; 1984-49; 1985-18; 1986-29; 1986-35; 1986-51;
1987-05; 1987-47